Physiological implications of hyperbaric oxygen tensions in isolated limb perfusion using melphalan: A pilot study

European Surgical Research

Volumn 28, Issue 3, 1996, Pages 235-244

  Vrouenraets, B C ^a   Kroon, B B R ^a   van de Merwe, S A ^b   Klaase, J M ^a   Broekmeyer Reurink, M P ^b   van Slooten, G W ^a   Nieweg, O E ^a   van der Zee, J ^b   van Dongen, J A ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Hyperbaric oxygen tensions; Isolated limb perfusion; Melanoma; Melphalan; Sarcoma; Subcutaneous oxygen tension; Tissue pH; Tumor pH

Indexed keywords

CHLORMETHINE DERIVATIVE; MELPHALAN;

ADULT; AGED; ARTERIAL OXYGEN TENSION; ARTICLE; BLOOD GAS; CLINICAL ARTICLE; CYTOTOXICITY; FEMALE; HUMAN; HYPERBARIC OXYGEN; LIMB PERFUSION; MALE; MUSCLE; OXYGEN TENSION; OXYGENATOR; PH; PRIORITY JOURNAL; SUBCUTANEOUS TISSUE;

EID: 0029872992     PISSN: 0014312X     EISSN: 14219921     Source Type: Journal    
DOI: 10.1159/000129462     Document Type: Article

References (48)

1. Kroon BBR: Regional isolation perfusion in melanoma of the limbs: Accomplishments, unsolved problems, future, Eur J Surg Oncol 1988; 14:101-110.
2. Vrouenraets BC, Klaase JM, Van Gecl AN, Eggermont AMM, Van dcr Zee J, Van de Mcrwe SA, Van Dongen JA, Kroon BBR: Regional isolated limb perfusion in patients with malignant melanoma, Onko-logie 1993:16:163-169.
3. Fontijne WPJ, Mook PH, Schraf-fordt Koops H, Oldhoff J, Wilde-vuur ChRH: Improved tissue perfusion during pressure regulated hyperthermic regional isolated perfusion, Cancer 1985:55:1455-1461.
4. Wieberdink J: Physiological Considerations Regarding Isolation Perfusion of the Extremities, Meppcl, Krips Rcpro, 1978.
5. Angel MF, Ramasastry SS, Swartz WM, Basford RE, Futrcll JW: Free radicals: Basic concepts concerning their chemistry, pathophysiology, and relevance to plastic surgery, Plast Reconstr Surg 1987:79:990-997.
6. Wieberdink J, Benckhuijsen C, Braat RP, Van Slootcn EA, Olthuis GAA: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions, Eur J Cancer Clin Oncol 1982:18:905-910.
7. Klaase JM, Kroon BBR, Van Gecl AN, Eggermont AMM, Franklin HR, Hart AAM: Patient and treatment related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities, Am J Surg 1994:167:618-620.
8. Belli F, Arienti F, Rivoltini L, Santi-nami M, Mascheroni L, Prada A, Amniatuna M, Marchesi E, Par-miani G, Cascinelli N, Vaglini M: Treatment of recurrent in transit métastasés from cutaneous melanoma by isolation perfusion in extra-corporeal circulation with interleukin-2 and lymphokine activated killer cells: A pilot study, Melanoma Res 1992;2:263-271.
9. Muchmore JH, Krementz, ET, Kcr-stein MD: Noninvasive evaluation of peripheral vasculature following regional hyperthermic chemotherapeutic perfusion (RHCP), Am Surg 1987:53:94-96.
10. Lejeune FJ, Licnard D, El Douaihy M, Vadoud Seyedi J, Ewalenko P: Results of 206 isolated limb perfusions for malignant melanoma, Eur J Surg Oncol 1989:15:510-519.
11. Ghusscn F, Kriiger I: Technical aspects of isolation extremity perfusion: Experimental studies and clinical experience, J Invest Surg 1989:2: 487-496.
12. Huber R, Mennicke C, Heitmann KU, Helling HJ, Huber PM: Membrane versus bubble oxygenator in hyperthermic regional perfusion: A prospective randomized clinical study, Eur Surg Res 1994:26:210-220.
13. Minor DR, Allen RE, Alberts D, Peng Y-M, Tardelli G, Hutchinson J: A clinical and pharmacokinetic study ofisolated limb perfusion with heat and ntelphalan for melanoma, Cancer 1985;55:2638-2644.
14. Hohenbergcr W, Meyer Th, Göhl J: Extremitätenperfusion beim malignen Melanom (Isolation perfusion in malignant melanoma), Chirurg 1994:65:175-185.
15. Krementz ET, Knudson L: The effect of increased oxygen tension on the tumoricidal effect on nitrogen mustard, Surgery 1961:50:266-271.
16. De Cosse JJ, Rogers LS: Influence of high-pressure oxygen and chemotherapy on the AMel 4 hamster melanoma, Cancer Res 1966:26:287-292.
17. Lienard D, Eggermont AMM, Schraffordt Koops H, Kroon BBR, Roscnkaimer F, Autier P, Lejeune FJ: Isolated perfusion of the limb with high-dose tumour necrosis fac-tor-alpha, interfcron-gamma and ntelphalan for melanoma stage III: Results of a multi-centre pilol study, Melanoma Res 1994;4(suppl 1):21-26.
18. Klaase JM, Kroon BBR, Van Sloo-ten GW, Van Dongen JA, Van de Mcrwe SA, Van dcr Zee J: Comparison between the use of whole blood versus a diluted perfusate in regional isolated perfusion by continuous monitoring of transcutancous oxygen tension: A pilot study, J Invest Surg 1994;7:249-258.
19. Bvme DS, McKay AJ, Scott RN, Blackic R, Hughes J, Burnside G, MacKic RM: Assessment of regional perfusion for melanoma by per-opcralive transcutaneous oxygen tension measurement, Reg Cancer Treat 1990;3:88-89.
20. Hjortdal VE, Timmenga EJ, Kjol-scth D, Brink Henriksen T, Stendcr Hansen E, Djurhuus JC, Gottrup F: Continuous direct tissue oxygen tension measurement: A new application for an intravascular oxygen sensor, Ann Chir Gynaecol 1991;80:8-13.
21. Hjortdahl VE, Henriksen TB, Kjol-seth D, Hansen ES, Djurhuus JC, Gottrup F: Tissue oxygen tension in myocutaneous flaps: Correlation with blood flow and blood gases, Eur J Surg 1991;157:307-311.
22. Van de Merwe SA, Van den Berg AP, Kroon BBR, Van den Berge AW, Klaase JM, Van der Zee J: Modification of human tumour and normal tissue pH during hyperthermic and normothermic antiblastic regional isolation perfusion for malignant melanoma: A pilot study, Int J Hyperthermia 1993:9:205-217.
23. Van der Zee J, Brockmeyer-Reurink MP, Van den Berg AP, Van Gecl BN, Jansen RFM, Kroon BBR, Van Wijk J, Hagenbeek A: Temperature distribution and pH changes during hyperthermic regional isolation perfusion, Eur J Cancer Clin Oncol 1989;25:1157-1163.
24. Krementz ET, Harlin R, Knudson 1.: The enhancement of chemotherapy by increased tissue oxygen tension, Cancer Chemothcr Rep 1960; 10:125-130.
25. Back N: Effect of oxygen tension on the in vitro and in vivo sensitivity of normal tissues and tumor cells to alkylating agents, Proc Am Assoc Cancer Res 1961:3:207.
26. Freund HR: Hyperbaric oxygenation in cancer (letter), Acta Oncol 1994;33:574.
27. Fontijne WPJ, Mook Ph, Elstrodt JM, Schraffordt Koops H, Oldhoff J, Wildevuur CHRH: Isolated hind-limb perfusion in dogs: The effect of perfusion pressures on the oxygen supply (p.Oj histogram) to the skeletal muscle, Surgery 1985:97:278-284.
28. Krementz ET, Saha S: Limb perfusion with mclphalan for melanoma by increased dose and dilution compared to standard technique: A pilot study, Reg Cancer Treat 1989;2: 233-237.
29. Hunt TK, Rabkin J, Jensen, IA, Jonsson K, Von Smitten K, Good-son WH: Tissue oxymetry: An interim report, World J Surg 1987:11: 126-132.
30. Vaupel P, Kallinowski F, OkuniefT P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review, Cancer Res 1989:49:6449-6465.
31. Waxman K, Annas C, Daudhters K, Tominaga GT, Scannell G: A method to determine the adequacy of resuscitation using tissue oxygen monitoring, J Trauma 1994:36:852-858.
32. Harkcn AH: Hydrogen oxygen concentration and oxygen uptake in an isolated canine hindlimb, J Appl Physiol 1976:40:1-5.
33. Burnett HF, Mabry CD, Westbrook KC, Campbell GS: Isolation regional perfusion: An experimental study, Surg Forum 1976;27:123-125.
34. Belboul A, Al-khaja N, Ericson C, Lofgrcn C, Thombolm C, Kurdi S, Roberts D, William-Olsson G: The effect of hypcroxia during cardiopulmonary bypass on blood cell rhcology and postoperative morbidity associated with cardiac surgery, J Extra-Corporeal Techno! 1989:23: 43-48.
35. Clark RE, Beauchamp RA, Magrath RAA, Brooks JD, Ferguson TB, Weldon CS: Comparison of bubble and membrane oxygenators in short and long perfusions, J Thorac Car-diovasc Surg 1979:78:655-666.
36. Van den Dungcn JJAM, Karliczek GF, Brenkcn U, Homan van der HeideJN, Wildcvuur CRH: Clinical study of blood trauma during perfusion with membrane and bubble oxygenators, J Thorac Cardiovasc Surg 1982;83:108-116.
37. Omlor G, Becker J, Gross G, Feindt P, Burger I: Haemolysis during hyperthermic limb perfusion, Reg Cancer Treat 1991:4:35.
38. Honig CR: Reserves and safety factors for O? Transport; in Honig CR (cd): Modern Cardiovascular Physiology, Boston, Little, Brown, 1988. pp 161-170.
39. Mueller-Klieser W, Vaupel P, Manz R: Tumour oxygenation under nor-mobaric and hyperbaric conditions, Br J Radiol 1983;56:559-564.
40. Scott RN, Blackie R, Kerr DJ, Wheldon TE, Kaye SB, MacKic RM, McKay AJ: Melphalan in isolated limb perfusion for malignant melanoma, bolus or divided dose, tissue levels, the pH effect: in Jakesz R, Rainer H (eds): Progress in Regional Cancer Therapy, Berlin, Springer Verlag, 1990. pp 195-200.
41. Siemann DW, Chapman M, Bci-kirch A: Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy, Int J Radiat Oncol Biol Phys 1991;20:287-289.
42. Atema A, Buurman KJH, Notc-boom E, Smets LA: Potentiation of DNA adduct formation and cytotoxicity of platinum-containing drugs by low pH, Int J Cancer 1993: 54:166-172.
43. Jähde E, Glüsenkamp K-H, Kliinder I, Hülscr DF, Tietzc L-F, Rajewsky MF: Hydrogen ion-mediated enhancement of cytotoxicity of bis-chlorocthylating drugs in rat mammary carcinoma cells in vitro, Cancer Res 1989:49:2965-2972.
44. Chaplin DJ, Acker B, Olive PL: Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs, Int J Radiat Oncol Biol Phys 1989: 16:1131-1135.
45. Skarsgard LD, Skwarchuk MW, Vinczan A, Kristi J, Chaplin DJ: The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake, Anticancer Res 1995; 15:219-224.
46. Fumcr RL, Brown RK: γ-Phenylalanine mustard (L-PAM): the first 25 years, Cancer Treat Rep 1980;64: 559-574.
47. Ross WC: Biological Alkylating Agents, London, Butterworth, 1962. p 99.
48. Stratford IJ, Adams GE, Godden J, Nolan J, Howells N, Timpson N: Potentiation of the anti-tumor effect of melphalan by the vasoactive agent, hydralazine, Br J Cancer 1988:58:122-124.